Cited by Macrophage-centered therapy strategies: a promising weapon in cancer immunotherapy

Recent progress in mRNA cancer vaccines DOI

Ruhui Yao,

C. Xie, Xiaojun Xia

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Jan. 28, 2024

The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application personalized antigens, structural optimization mRNA, alternative RNA-based vectors efficient targeted delivery vectors. Clinical trials are currently underway for various that encode tumor-associated antigens (TAAs), tumor-specific (TSAs), or immunomodulators. In this paper, we summarize mRNA emergence expression in vaccines. We begin by reviewing advancement utilization state-of-the-art lipid nanoparticles (LNPs), followed presenting primary classifications clinical applications Collectively, emerging as a central focus immunotherapy, offering potential to address multiple treatment, either standalone therapies combination with current treatments.

Language: Английский

Citations

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy DOI

Na Li,

Shinan Geng,

Zhenzhen Dong

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: June 1, 2024

Abstract Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during previous ten years. However, its effectiveness treating solid tumors is still lacking, necessitating exploration alternative immunotherapies that can overcome significant challenges faced by current CAR-T cells. CAR-based immunotherapy against shows promise with emergence macrophages, which possess robust phagocytic abilities, antigen-presenting functions, and ability to modify tumor microenvironment stimulate adaptive responses. This paper presents a thorough examination latest progress CAR-M therapy, covering both basic scientific studies clinical trials. study examines primary obstacles hindering realization complete potential as well strategies be employed these hurdles. With revolutionary technologies like situ genetic modification, synthetic biology techniques, biomaterial-supported gene transfer, provide wider array resources manipulating tumor-associated we suggest combining advanced methods will result creation new era therapy demonstrates improved efficacy, safety, availability. Graphical

Language: Английский

Citations

Chimeric antigen receptor therapy meets mRNA technology DOI

Jiacai Wu,

Weigang Wu,

Boping Zhou

et al.

Trends in biotechnology, Journal Year: 2023, Volume and Issue: 42(2), P. 228 - 240

Published: Sept. 21, 2023

Language: Английский

Citations

CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond DOI

Jialin Lu,

Yuqing Ma,

Q. Quentin Li

et al.

Biomarker Research, Journal Year: 2024, Volume and Issue: 12(1)

Published: Aug. 23, 2024

Abstract With the advent of adoptive cellular therapy, chimeric antigen receptor (CAR)-T cell therapy has gained widespread application in cancer treatment and demonstrated significant efficacy against certain hematologic malignancies. However, due to limitations CAR-T treating solid tumors, other immune cells are being modified with CAR address this issue. Macrophages have emerged as a promising option, owing their extensive functions, which include presentation, powerful tumor phagocytosis, particularly active trafficking microenvironment. Leveraging unique advantages, CAR-macrophages (CAR-M) expected enhance effectiveness treatments novel form immunotherapy, potentially overcoming major challenges associated CAR-T/NK therapy. This review outlines primary mechanism underlying CAR-M recent progressions while also discussing further applications.

Language: Английский

Citations

In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials DOI

Shihong Nie,

Yuyang Qin,

Liyuan Ou

et al.

Advanced Materials, Journal Year: 2024, Volume and Issue: 36(15)

Published: Jan. 17, 2024

In the past decade, adoptive cell therapy with chimeric antigen receptor-T (CAR-T) cells has revolutionized cancer treatment. However, complexity and high costs involved in manufacturing current greatly inhibit its widespread availability access. To address this, situ therapy, which directly reprograms immune inside body, recently been developed as a promising alternative. Here, an overview of recent progress development synthetic nanomaterials is provided to deliver plasmid DNA or mRNA for reprogramming T macrophages, focusing especially on CAR therapies. Also, main challenges are discussed some approaches overcome these barriers fulfill clinical applications proposed.

Language: Английский

Citations

Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders DOI

Runxuan Chu, Yi Wang, Jianglong Kong

et al.

Journal of Materials Chemistry B, Journal Year: 2024, Volume and Issue: 12(20), P. 4759 - 4784

Published: Jan. 1, 2024

This paper provides a comprehensive review of the structure, composition, and applications LNPs in treatment hepatic disorders offers insights into prospects challenges future development LNPs.

Language: Английский

Citations

Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer DOI

Yizhao Chen,

Qianling Xin,

Mengjuan Zhu

et al.

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

After significant advancements in tumor treatment, personalized cell therapy based on chimeric antigen receptors (CAR) holds promise for transforming the management of various diseases. CAR-T therapy, first approved CAR product, has demonstrated therapeutic potential treating infectious diseases, autoimmune disorders, and fibrosis. CAR-macrophages (CAR-Ms) are emerging as a promising approach immune particularly solid highlighting feasibility using macrophages to eliminate pathogens abnormal cells.

Language: Английский

Citations

Engineering innate immune cells for cancer immunotherapy DOI

Mubin Tarannum,

Xizhong Ding,

Marta Barisa

et al.

Nature Biotechnology, Journal Year: 2025, Volume and Issue: 43(4), P. 516 - 533

Published: April 1, 2025

Language: Английский

Citations

The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies DOI

Shuairan Zhang, Dong Hang,

Xiuli Jin

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: 1871(3), P. 167676 - 167676

Published: Jan. 18, 2025

Language: Английский

Citations

Harnessing myeloid cells in cancer DOI

Suyeon Park, Ekaterina Pylaeva, Vikas Bhuria

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 6, 2025

Cancer-associated myeloid cells due to their plasticity play dual roles in both promoting and inhibiting tumor progression. Myeloid with immunosuppressive properties a critical role anti-cancer immune regulation. Cells of different origin, such as associated macrophages (TAMs), neutrophils (TANs), derived suppressor (also called MDSCs) eosinophils are often expanded cancer patients significantly influence survival, but also the outcome therapies. For this reason, variety preclinical clinical studies modulate activity these have been conducted, however without successful date. In review, pro-tumor cells, cell-specific therapeutic targets, vivo on cell re-polarization impact immunotherapies/genetic engineering addressed. This paper summarizes ongoing trials concept chimeric antigen receptor macrophage (CAR-M) therapies, suggests future research perspectives, offering new opportunities development novel treatment strategies.

Language: Английский

Citations